GENENTECH, INC for GENENTECH INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 20, 2017 | $890,000 | Replaced |
| 1st Quarter - Amendment | Apr 20, 2017 | $880,000 | Yes |
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Trade negotiations and Transatlantic Trade Partnership (TTIP). Issues related to trade policy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Medical/Disease Research/Clinical Labs MED
Bioterrorism preparedness and development of medical countermeasures.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Taxation/Internal Revenue Code TAX
Issues related to corporate tax reform. General Tax Issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| MATTHEW L SULKALA New | — |
Copyright/Patent/Trademark CPT
Intellectual Property and Process Patent Issues. Patent Litigation Reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| KATHERINE RAAB | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Pharmacy PHA
Monitor Drug Safety and pedigree legislation. 340B Drug Discount Program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Health Issues HCR
Provide guidance and strategic counsel with regard to regulations and legislation that could impact, pharmaceutical and biotechnology manufacturers. Policies related to the 340B Drug Discount Program. Drug pricing issues. HR 1628, The American Health Care Act. S. 469 Affordable and Safe Prescription Drug Importation Act. Prescription Drug User Fee Act Agreements. S.204/H.R.878, Trickett Wendler Right to Try Act of 2017. Issues related to the implementation of the follow-on biologics provisions in P.L. 111148 "Patient Protection and Affordable Care Act". Stockpiling of medical countermeasures in advance of a potential pandemic. Implementation of issues related to the Security and Accountability Act (P.L. 113-54); Issues related to Pharma supply chain.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| KATHERINE RAAB | — |
| MATTHEW L SULKALA New | — |
| ANDREW WESLEY WOMACK | — |
Medicare/Medicaid MMM
Implementation of Medicare pharmaceutical coverage and reimbursement issues; Medicare Part B reimbursement for physicians and implementation of related provisions of the Affordable Care Act; reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B drug payment model. Policies relating to 340B Program. Issues relating to the repeal and replacement of the Affordable Care Act (HR 1628, The American Health Care Act).
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| KATHERINE RAAB | — |
| MATTHEW L SULKALA New | — |
| ANDREW WESLEY WOMACK | — |
Budget/Appropriations BUD
Issues related to FDA and HHS program funding in the FY17 Labor, Health and Human Services, and Education and Related Agencies, and FY17 Agriculture, Rural Developments, Food and Drug Administrations, and Related Agencies Appropriations bills.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | — |
| KATHERINE RAAB | — |
| MATTHEW L SULKALA | — |
| ANDREW WESLEY WOMACK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.